EA201000926A1 - Пиперазины в качестве агентов против ожирения - Google Patents

Пиперазины в качестве агентов против ожирения

Info

Publication number
EA201000926A1
EA201000926A1 EA201000926A EA201000926A EA201000926A1 EA 201000926 A1 EA201000926 A1 EA 201000926A1 EA 201000926 A EA201000926 A EA 201000926A EA 201000926 A EA201000926 A EA 201000926A EA 201000926 A1 EA201000926 A1 EA 201000926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperasins
compounds
agents against
against obesity
dyslipidemia
Prior art date
Application number
EA201000926A
Other languages
English (en)
Russian (ru)
Inventor
Джозеф У. Бойд
Джилс А. Браун
Майкл Хиггинботтом
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201000926A1 publication Critical patent/EA201000926A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EA201000926A 2007-12-05 2008-12-05 Пиперазины в качестве агентов против ожирения EA201000926A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0702696 2007-12-05
US2298308P 2008-01-23 2008-01-23
PCT/EP2008/066877 WO2009071658A1 (en) 2007-12-05 2008-12-05 Piperazines as anti-obesity agents

Publications (1)

Publication Number Publication Date
EA201000926A1 true EA201000926A1 (ru) 2011-02-28

Family

ID=40409928

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000926A EA201000926A1 (ru) 2007-12-05 2008-12-05 Пиперазины в качестве агентов против ожирения

Country Status (17)

Country Link
US (3) US20110059969A1 (cg-RX-API-DMAC7.html)
EP (1) EP2229362A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011506294A (cg-RX-API-DMAC7.html)
KR (1) KR20100093104A (cg-RX-API-DMAC7.html)
CN (1) CN102026975A (cg-RX-API-DMAC7.html)
AU (1) AU2008333173A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819989A2 (cg-RX-API-DMAC7.html)
CA (1) CA2707555A1 (cg-RX-API-DMAC7.html)
CO (1) CO6280487A2 (cg-RX-API-DMAC7.html)
CR (1) CR11479A (cg-RX-API-DMAC7.html)
DO (1) DOP2010000167A (cg-RX-API-DMAC7.html)
EA (1) EA201000926A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010234A (cg-RX-API-DMAC7.html)
IL (1) IL205874A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010006259A (cg-RX-API-DMAC7.html)
WO (1) WO2009071658A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003976B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093248B2 (en) * 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
KR20100097701A (ko) * 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)乙醇的制备方法
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420193A1 (de) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
BR9709529A (pt) 1996-06-06 1999-08-10 Smithkline Beecham P L C Socie Fragmentos de leptina (proteína ob)
US6057337A (en) * 1998-02-02 2000-05-02 Shiseido Co., Ltd. 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
MXPA05013365A (es) 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
US7700597B2 (en) * 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
EP1991211A1 (en) 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
KR20100097701A (ko) 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
KR20100097725A (ko) 2007-12-05 2010-09-03 아스트라제네카 아베 신규 화합물 ⅲ
US8093248B2 (en) 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
JP2011522009A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物vii
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物v
AU2009254557A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab (Publ) Small molecule leptin receptor modulators
MX2010013359A (es) 2008-06-04 2011-04-07 Astrazeneca Ab Nuevos derivados de piridina como mimeticos moduladores del receptor de leptina.

Also Published As

Publication number Publication date
BRPI0819989A2 (pt) 2015-05-12
DOP2010000167A (es) 2010-06-30
CA2707555A1 (en) 2009-06-11
CO6280487A2 (es) 2011-05-20
MX2010006259A (es) 2010-08-23
KR20100093104A (ko) 2010-08-24
US7851471B2 (en) 2010-12-14
US20110059969A1 (en) 2011-03-10
ZA201003976B (en) 2011-04-28
ECSP10010234A (es) 2010-07-30
US20110046135A1 (en) 2011-02-24
AU2008333173A1 (en) 2009-06-11
WO2009071658A1 (en) 2009-06-11
EP2229362A1 (en) 2010-09-22
CN102026975A (zh) 2011-04-20
US20090181967A1 (en) 2009-07-16
JP2011506294A (ja) 2011-03-03
CR11479A (es) 2010-07-19
IL205874A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
EA200901651A1 (ru) Новые тиреоидные соединения для лечения заболеваний, связанных с нарушением обмена веществ
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
EA201000050A1 (ru) Замещенные бициклолактамные соединения
PE20120018A1 (es) Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2007002841A1 (es) Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2010006259A (es) Piperazinas como agentes antiobesidad.
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.